Endometrial Cancer

Obstetrics and Gynecology

Volumn 125, Issue 4, 2015, Pages 1006-1026

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; GESTAGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; HORMONE;

AGE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CYTOREDUCTIVE SURGERY; DISEASE CLASSIFICATION; ENDOMETRIUM CANCER; GENETIC PREDISPOSITION; GYNECOLOGIC ONCOLOGIST; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INCIDENTAL FINDING; LAPAROTOMY; METASTASIS; MINIMALLY INVASIVE SURGERY; OVARIAN PRESERVATION; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SMOKING; SURGICAL APPROACH; ADJUVANT CHEMOTHERAPY; CONSERVATIVE TREATMENT; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY PRESERVATION; OVARIECTOMY; SALPINGECTOMY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CYTOREDUCTION SURGICAL PROCEDURES; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HORMONES; HUMANS; HYSTERECTOMY; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; OVARIECTOMY; RISK FACTORS; SALPINGECTOMY;

EID: 84929940423     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/01.AOG.0000462977.61229.DE     Document Type: Review

References (165)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29. (Level II-3) [PubMed]
2. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(suppl 1):S105–43. (Level III) [PubMed] [Full Text]
3. Sorosky JI. Endometrial cancer. Obstet Gynecol 2008; 111:436–47. (Level III) [PubMed] [Obstetrics & Gynecology]
4. HowladerN,NooneAM,KrapchoM,GarshellJ,MillerD, Altekruse SF, et al, editors. SEER Cancer Statistics Review, 1975–2011. Bethesda (MD): National Cancer Institute; 2014. Available at: http://seer.cancer.gov/csr/ 1975_2011. Retrieved January 20, 2014. (Level II-3)
5. Oliver KE, Enewold LR, Zhu K, Conrads TP, Rose GS, Maxwell GL, et al. Racial disparities in histopathologic characteristics of uterine cancer are present in older, not younger blacks in an equal-access environment. Gynecol Oncol 2011;123:76–81. (Level II-3) [PubMed] [Full Text]
6. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA. Epithelial tumours and related lesions. In: Tavassoli FA, Devilee P, editors. Pathology and genetics of tumours of the breast and female genital organs. World Health Organization classification of tumours. Lyon (France): IARC Press; 2003. p. 221–32. (Level III)
7. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:403–12. (Level III) [PubMed]
8. Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010;28:788–92. (Level II-2) [PubMed] [Full Text]
9. Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812–9. (Level II-2) [PubMed] [Full Text]
10. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol 1994;52:373–8. (Level III) [PubMed]
11. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642–6. (Level II-3) [PubMed] [Full Text]
12. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995;26: 1260–7. (Level II-3) [PubMed]
13. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000;24: 797–806. (Level II-3) [PubMed]
14. Rabban JT, Zaloudek CJ. Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis. Pathology 2007;39:125–33. (Level III) [PubMed]
15. Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol 1991;40:207–17. (Level III) [PubMed]
16. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569–78. (Meta-analysis) [PubMed] [Full Text]
17. Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3:565–74. (Level III) [PubMed]
18. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2010;19:3119–30. (Meta-analysis) [PubMed] [Full Text]
19. Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 1998;148: 234–40. (Level II-2) [PubMed] [Full Text]
20. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension 1999;34:320–5. (Level II-2) [PubMed] [Full Text]
21. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer [published erratum appears in Cancer 2006;107:2314]. Cancer 2006;106:2376–81. (Level II-2) [PubMed] [Full Text]
22. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993;81:265–71. (Level II-2) [PubMed] [Obstetrics & Gynecology]
23. Grady D, Ernster VL. Hormone replacement therapy and endometrial cancer: are current regimens safe? J Natl Cancer Inst 1997;89:1088–9. (Level III) [PubMed] [Full Text]
24. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110–6. (Level II-2) [PubMed] [Full Text]
25. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985;313:969–72. (Level II-2) [PubMed] [Full Text]
26. Strom BL, Schinnar R, Weber AL, Bunin G, Berlin JA, Baumgarten M, et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 2006;164:775–86. (Level II-2) [PubMed] [Full Text]
27. Allen NE, Tsilidis KK, Key TJ, Dossus L, Kaaks R, Lund E, et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol 2010;172:1394–403. (Level II-2) [PubMed] [Full Text]
28. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. Women’s Health Initiative Investigators. JAMA 2003;290:1739–48. (Level I) [PubMed] [Full Text]
29. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Million Women Study Collaborators. Lancet 2005; 365:1543–51. (Level II-2) [PubMed] [Full Text]
30. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–7. (Level II-2) [PubMed] [Full Text]
31. Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer 2011;128:1644–51. (Level II-2) [PubMed] [Full Text]
32. Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:202–16. (Level III) [PubMed] [Obstetrics & Gynecology]
33. Sismondi P, Biglia N, Volpi E, Giai M, de Grandis T. Tamoxifen and endometrial cancer. Ann N Y Acad Sci 1994;734:310–21. (Level III) [PubMed]
34. Bissett D, Davis JA, George WD. Gynaecological monitoring during tamoxifen therapy. Lancet 1994;344:1244. (Level III) [PubMed]
35. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527–37. (Level I) [PubMed]
36. Tamoxifen and uterine cancer. Committee Opinion No. 601. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;123:1394–7. (Level III) [PubMed] [Obstetrics & Gynecology]
37. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88. (Level I) [PubMed] [Full Text]
38. Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;158:604–14. (Level III) [PubMed] [Full Text]
39. Simon JA, Lin VH, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Ospemifene Study Group. Menopause 2013;20:418–27. (Level I) [PubMed] [Full Text]
40. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984;64:417–20. (Level III) [PubMed] [Obstetrics & Gynecology]
41. Lachance JA, Everett EN, Greer B, Mandel L, Swisher E, Tamimi H, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2006;101: 470–5. (Level II-3) [PubMed] [Full Text]
42. SolimanPT,OhJC,SchmelerKM,SunCC,SlomovitzBM, Gershenson DM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol 2005;105:575–80. (Level II-3) [PubMed] [Obstetrics & Gynecology]
43. Thomas CC, Wingo PA, Dolan MS, Lee NC, Richardson LC. Endometrial cancer risk among younger, overweight women. Obstet Gynecol 2009;114:22–7. (Level II-2) [PubMed] [Obstetrics & Gynecology]
44. Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 2013;129:277–84. (Level II-3) [PubMed] [Full Text]
45. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women’s Health Study. Am J Epidemiol 1996;143:1195–202. (Level II-3) [PubMed] [Full Text]
46. Parazzini F, Negri E, La Vecchia C, Benzi G, Chiaffarino F, Polatti A, et al. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer 1998;76:784–6. (Level II-2) [PubMed] [Full Text]
47. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 2013;22:1931–43. (Level I) [PubMed] [Full Text]
48. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 1991;49:186–90. (Level II-2) [PubMed]
49. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002;57:120–8. (Level I) [PubMed]
50. Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices [published erratum appears in Contraception 2008;77:138]. Contraception 2007;75:S60–9. (Level III) [PubMed] [Full Text]
51. Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 2008;121:501–508.e3. (Meta-analysis) [PubMed]
52. Barrow E, Hill J, Evans DG. Cancer risk in Lynch syndrome. Fam Cancer 2013;12:229–40. (Level III) [PubMed]
53. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677–85. (Level II-3) [PubMed]
54. Lynch syndrome. Practice Bulletin No. 147. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;124:1042–54. (Level III) [PubMed] [Obstetrics & Gynecology]
55. Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Society of Gynecologic Oncologists Education Committee. Gynecol Oncol 2007;107:159–62. (Level III) [PubMed] [Full Text]
56. Eng C. PTEN: one gene, many syndromes. Hum Mutat 2003;22:183–98. (Level III) [PubMed]
57. Levine DA, Lin O, Barakat RR, Robson ME, McDermott D, Cohen L, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol 2001;80: 395–8. (Level II-3) [PubMed]
58. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. J Natl Cancer Inst 2002;94:1358–65. (Level II-3) [PubMed] [Full Text]
59. Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Hereditary Ovarian Cancer Clinical Study Group. Gynecol Oncol 2007;104:7–10. (Level II-3) [PubMed] [Full Text]
60. Lu KH, Kauff ND. Does a BRCA mutation plus tamoxifen equal hysterectomy? Gynecol Oncol 2007;104:3–4. (Level III)[PubMed] [Full Text]
61. Hereditary breast and ovarian cancer syndrome. ACOG Practice Bulletin No. 103. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 113:957–66. (Level III) [PubMed] [Obstetrics & Gynecology]
62. Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995;56:29–33. (Level II-3) [PubMed]
63. Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients. Cancer 2006;107:1823–30. (Level II-3) [PubMed] [Full Text]
64. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035–41. (Level II-3) [PubMed]
65. Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:11–8. (Level II-3) [PubMed] [Full Text]
66. McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecologic Oncology Group. Gynecol Oncol 2007;105:508–16. (Level III) [PubMed] [Full Text]
67. Abu-Rustum NR, Gomez JD, Alektiar KM, Soslow RA, Hensley ML, Leitao MM Jr, et al. The incidence of isolated paraaortic nodal metastasis in surgically staged endometrial cancer patients with negative pelvic lymph nodes. Gynecol Oncol 2009;115:236–8. (Level III) [PubMed] [Full Text]
68. Abu-Rustum NR, Khoury-Collado F, Pandit-Taskar N, Soslow RA, Dao F, Sonoda Y, et al. Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma? Gynecol Oncol 2009;113:163–9. (Level III) [PubMed] [Full Text]
69. Khoury-Collado F, Murray MP, Hensley ML, Sonoda Y, Alektiar KM, Levine DA, et al. Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecol Oncol 2011;122:251–4. (Level II-3) [PubMed] [Full Text]
70. Diagnosis of abnormal uterine bleeding in reproductive-aged women. Practice Bulletin No. 128. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:197–206. (Level III) [PubMed] [Obstetrics & Gynecology]
71. The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. ACOG Committee Opinion No. 440. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;114:409–11. (Level III) [Obstetrics & Gynecology]
72. Timmermans A, Opmeer BC, Khan KS, Bachmann LM, Epstein E, Clark TJ, et al. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 2010;116:160–7. (Meta-analysis) [PubMed] [Obstetrics & Gynecology]
73. Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000;89:1765–72. (Meta-analysis) [PubMed]
74. Epstein E, Ramirez A, Skoog L, Valentin L. Dilatation and curettage fails to detect most focal lesions in the uterine cavity in women with postmenopausal bleeding. Acta Obstet Gynecol Scand 2001;80:1131–6. (Level III) [PubMed] [Full Text]
75. Lee DO, Jung MH, Kim HY. Prospective comparison of biopsy results from curettage and hysteroscopy in postmenopausal uterine bleeding. J Obstet Gynaecol Res 2011;37:1423–6. (Level III) [PubMed] [Full Text]
76. Epstein E. Management of postmenopausal bleeding in Sweden: a need for increased use of hydrosonography and hysteroscopy. Acta Obstet Gynecol Scand 2004;83:89–95. (Level III) [PubMed] [Full Text]
77. Ronghe R, Gaudoin M. Women with recurrent postmenopausal bleeding should be re-investigated but are not more likely to have endometrial cancer. Menopause Int 2010;16:9–11. (Level II-2) [PubMed]
78. Smith PP, O’Connor S, Gupta J, Clark TJ. Recurrent postmenopausal bleeding: a prospective cohort study. J Minim Invasive Gynecol 2014;21:799–803. (Level II-2) [PubMed] [Full Text]
79. Han SS, Lee SH, Kim DH, Kim JW, Park NH, Kang SB, et al. Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer. Acta Obstet Gynecol Scand 2010;89:168–74. (Level II-3) [PubMed] [Full Text]
80. Kitajima K, Murakami K, Yamasaki E, Fukasawa I, Inaba N, Kaji Y, et al. Accuracy of 18F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. AJR Am J Roentgenol 2008;190:1652–8. (Level III) [PubMed] [Full Text]
81. Kitajima K, Murakami K, Yamasaki E, Kaji Y, Sugimura K. Accuracy of integrated FDG-PET/contrast-enhanced CT in detecting pelvic and paraaortic lymph node metastasis in patients with uterine cancer. Eur Radiol 2009;19:1529–36. (Level III) [PubMed]
82. Nakai G, Matsuki M, Inada Y, Tatsugami F, Tanikake M, Narabayashi I, et al. Detection and evaluation of pelvic lymph nodes in patients with gynecologic malignancies using body diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr 2008;32:764–8. (Level III) [PubMed]
83. Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, Rueda B, Goodman A, del Carmen MG. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol 2008;110:293–8. (Level II-3) [PubMed] [Full Text]
84. Chan JK, Kapp DS. Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 2007;8:831–41. (Level III) [PubMed]
85. Diaz-Montes TP, Zahurak ML, Giuntoli RL 2nd, Gardner GJ, Bristow RE. Uterine cancer in Maryland: impact of surgeon case volume and other prognostic factors on short-term mortality. Gynecol Oncol 2006;103:1043–7. (Level II-3) [PubMed] [Full Text]
86. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecologic Oncology Group [published erratum appears in Gynecol Oncol 2004;94:241–2]. Gynecol Oncol 2004;92:744–51. (Level I) [PubMed] [Full Text]
87. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707–16. (Level I) [PubMed] [Full Text]
88. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. ASTEC study group [published erratum appears in Lancet 2009;373:1764]. Lancet 2009;373:125–36. (Level I) [PubMed] [Full Text]
89. Yost KJ, Cheville AL, Al-Hilli MM, Mariani A, Barrette BA, McGree ME, et al. Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet Gynecol 2014;124:307–15. (Level II-2) [PubMed] [Obstetrics & Gynecology]
90. Abu-RustumNR,AlektiarK,IasonosA,LevG,SonodaY, Aghajanian C, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006;103:714–8. (Level II-3) [PubMed] [Full Text]
91. Todo Y, Yamamoto R, Minobe S, Suzuki Y, Takeshi U, Nakatani M, et al. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecol Oncol 2010;119:60–4. (Level II-3) [PubMed] [Full Text]
92. Janda M, Gebski V, Brand A, Hogg R, Jobling TW, Land R, et al. Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial. Lancet Oncol 2010;11:772–80. (Level I) [PubMed]
93. Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study [published erratum appears in J Clin Oncol 2010;28:2805]. J Clin Oncol 2009;27:5337–42. (Level I) [PubMed] [Full Text]
94. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009;27:5331–6. (Level I) [PubMed] [Full Text]
95. Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study [published erratum appears in J Clin Oncol 2012;30(13):1570]. J Clin Oncol 2012;30:695–700. (Level I) [PubMed] [Full Text]
96. Palomba S, Falbo A, Mocciaro R, Russo T, Zullo F. Laparoscopic treatment for endometrial cancer: a meta-analysis of randomized controlled trials (RCTs). Gynecol Oncol 2009;112:415–21. (Meta-analysis) [PubMed] [Full Text]
97. Palomba S, Falbo A, Russo T, Zullo F. Updating of a recent meta-analysis of randomized controlled trials to assess the safety and the efficacy of the laparoscopic surgery for treating early stage endometrial cancer. Gynecol Oncol 2009;114:135–6. (Meta-analysis) [PubMed] [Full Text]
98. Lim PC, Kang E, Park do H. A comparative detail analysis of the learning curve and surgical outcome for robotic hysterectomy with lymphadenectomy versus laparoscopic hysterectomy with lymphadenectomy in treatment of endometrial cancer: a case-matched controlled study of the first one hundred twenty two patients. Gynecol Oncol 2011;120:413–8. (Level II-3) [PubMed] [Full Text]
99. Boggess JF, Gehrig PA, Cantrell L, Shafer A, Ridgway M, Skinner EN, et al. A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy. Am J Obstet Gynecol 2008;199:360.e1–9. (Level II-3) [PubMed] [Full Text]
100. Coronado PJ, Herraiz MA, Magrina JF, Fasero M, Vidart JA. Comparison of perioperative outcomes and cost of robotic-assisted laparoscopy, laparoscopy and laparotomy for endometrial cancer. Eur J Obstet Gynecol Reprod Biol 2012;165:289–94. (Level II-3) [PubMed] [Full Text]
101. Gaia G, Holloway RW, Santoro L, Ahmad S, Di Silverio E, Spinillo A. Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches: a systematic review. Obstet Gynecol 2010;116:1422–31. (Meta-analysis) [PubMed] [Obstetrics & Gynecology]
102. Barnett JC, Judd JP, Wu JM, Scales CD Jr, Myers ER, Havrilesky LJ. Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer. Obstet Gynecol 2010;116:685–93. (Level III) [PubMed] [Obstetrics & Gynecology]
103. Wright JD, Burke WM, Wilde ET, Lewin SN, Charles AS, Kim JH, et al. Comparative effectiveness of robotic versus laparoscopic hysterectomy for endometrial cancer. J Clin Oncol 2012;30:783–91. (Level II-3) [PubMed] [Full Text]
104. Yu X, Lum D, Kiet TK, Fuh KC, Orr J Jr, Brooks RA, et al. Utilization of and charges for robotic versus laparoscopic versus open surgery for endometrial cancer. J Surg Oncol 2013;107:653–8. (Level III) [PubMed] [Full Text]
105. American College of Obstetricians and Gynecologists. Power morcellation and occult malignancy in gynecologic surgery: a special report. Washington, DC: American College of Obstetricians and Gynecologists; 2014. (Level III) [Full Text]
106. Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet 2009;105:109. (Level III) [PubMed] [Full Text]
107. Smith SM, Hoffman MS. The role of vaginal hysterectomy in the treatment of endometrial cancer. Am J Obstet Gynecol 2007;197:202.e1–e6; discussion 202.e6–e7. (Level III) [PubMed] [Full Text]
108. Chan JK, Lin YG, Monk BJ, Tewari K, Bloss JD, Berman ML. Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women. Obstet Gynecol 2001;97:707–11. (Level III) [PubMed] [Obstetrics & Gynecology]
109. Berretta R, Merisio C, Melpignano M, Rolla M, Ceccaroni M, DE Ioris A, et al. Vaginal versus abdominal hysterectomy in endometrial cancer: a retrospective study in a selective population. Int J Gynecol Cancer 2008;18:797–802. (Level II-3) [PubMed]
110. Massi G, Savino L, Susini T. Vaginal hysterectomy versus abdominal hysterectomy for the treatment of stage I endometrial adenocarcinoma. Am J Obstet Gynecol 1996; 174:1320–6. (Level II-3) [PubMed]
111. Susini T, Massi G, Amunni G, Carriero C, Marchionni M, Taddei G, et al. Vaginal hysterectomy and abdominal hysterectomy for treatment of endometrial cancer in the elderly. Gynecol Oncol 2005;96:362–7. (Level II-3) [PubMed] [Full Text]
112. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419–27. (Level I) [PubMed] [Obstetrics & Gynecology]
113. Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. ASTEC/EN.5 Study Group. Lancet 2009;373:137–46. (Meta-analysis) [PubMed] [Full Text]
114. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404–11. (Level I) [PubMed] [Full Text]
115. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. PORTEC Study Group. Lancet 2010;375:816–23. (Level I) [PubMed] [Full Text]
116. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. PORTEC Study Group. Gynecol Oncol 2003;89:201–9. (Level I) [PubMed] [Full Text]
117. Huh WK, Straughn JM Jr, Mariani A, Podratz KC, Havrilesky LJ, Alvarez-Secord A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer 2007;17:886–9. (Level II-2) [PubMed]
118. Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys 2003;56:1366–72. (Level III) [PubMed]
119. Nout RA, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009;27:3547–56. (Level I) [PubMed] [Full Text]
120. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium [published erratum appears in Int J Gynaecol Obstet 2010;108:176]. Int J Gynaecol Obstet 2009;105:103–4. (Level III) [PubMed]
121. Wolfson AH, Sightler SE, Markoe AM, Schwade JG, Averette HE, Ganjei P, et al. The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 1992;45:142–6. (Level III) [PubMed]
122. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000;78:85–91. (Level III) [PubMed] [Full Text]
123. Lambrou NC, Gomez-Marin O, Mirhashemi R, Beach H, Salom E, Almeida-Parra Z, et al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004;93:653–8. (Level III) [PubMed] [Full Text]
124. Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol 1997;67:56–60. (Level II-3) [PubMed] [Full Text]
125. Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994;52:237–40. (Level III) [PubMed]
126. Shih KK, Yun E, Gardner GJ, Barakat RR, Chi DS, Leitao MM Jr. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol Oncol 2011; 122:608–11. (Level III) [PubMed] [Full Text]
127. Campagnutta E, Giorda G, De Piero G, Sopracordevole F, Visentin MC, Martella L, et al. Surgical treatment of recurrent endometrial carcinoma. Cancer 2004;100: 89–96. (Level III) [PubMed] [Full Text]
128. Awtrey CS, Cadungog MG, Leitao MM, Alektiar KM, Aghajanian C, Hummer AJ, et al. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 2006; 102:480–8. (Level III) [PubMed] [Full Text]
129. Dowdy SC, Mariani A, Cliby WA, Haddock MG, Petersen IA, Sim FH, et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol 2006;101:280–6. (Level III)[PubMed] [Full Text]
130. Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999;75:99–102. (Level III) [PubMed] [Full Text]
131. Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996; 60:288–91. (Level III) [PubMed] [Full Text]
132. Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010;118:14–8. (Meta-analysis) [PubMed] [Full Text]
133. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24:36–44. (Level I) [PubMed] [Full Text]
134. Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, et al. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol Oncol 2009;112:337–41. (Level II-3) [PubMed] [Full Text]
135. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol 2009;112:543–52. (Level I) [PubMed] [Full Text]
136. Geller MA, Ivy J, Dusenbery KE, Ghebre R, Isaksson Vogel R, Argenta PA. A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the “sandwich” method for high risk endometrial carcinoma. Gynecol Oncol 2010;118:19–23. (Level III) [PubMed] [Full Text]
137. Geller MA, Ivy JJ, Ghebre R, Downs LS Jr, Judson PL, Carson LF, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 2011;121:112–7. (Level III) [PubMed] [Full Text]
138. Onda T, Yoshikawa H, Mizutani K, Mishima M, Yokota H, Nagano H, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997;75:1836–41. (Level II-3) [PubMed] [Full Text]
139. Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22:2159–66. (Level I) [PubMed] [Full Text]
140. Sovak MA, Hensley ML, Dupont J, Ishill N, Alektiar KM, Abu-Rustum N, et al. Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study. Gynecol Oncol 2006;103:451–7. (Level III) [PubMed] [Full Text]
141. Hidaka T, Nakamura T, Shima T, Yuki H, Saito S. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma. J Obstet Gynaecol Res 2006;32:330–7. (Level III) [PubMed]
142. Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:4–9. (Level III) [PubMed] [Full Text]
143. Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:10–4. (Level II-3) [PubMed] [Full Text]
144. Duska LR, Garrett A, Rueda BR, Haas J, Chang Y, Fuller AF. Endometrial cancer in women 40 years old or younger. Gynecol Oncol 2001;83:388–93. (Level III) [PubMed] [Full Text]
145. Shah MM, Wright JD. Management of endometrial cancer in young women. Clin Obstet Gynecol 2011;54: 219–25. (Level III) [PubMed]
146. Erkanli S, Ayhan A. Fertility-sparing therapy in young women with endometrial cancer: 2010 update. Int J Gynecol Cancer 2010;20:1170–87. (Level III) [PubMed]
147. Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998;91:349–54. (Level II-3) [PubMed] [Obstetrics & Gynecology]
148. Gitsch G, Friedlander ML, Wain GV, Hacker NF. Uterine papillary serous carcinoma. A clinical study. Cancer 1995;75:2239–43. (Level III) [PubMed]
149. Navarria I, Usel M, Rapiti E, Neyroud-Caspar I, Pelte MF, Bouchardy C, et al. Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol 2009;114:448–51. (Level II-3) [PubMed] [Full Text]
150. Daniel AG, Peters WA 3rd. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 1988;71:612–4. (Level II-3) [PubMed] [Obstetrics & Gynecology]
151. Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995;86:38–42. (Level II-3) [PubMed] [Obstetrics & Gynecology]
152. Kim SH, Kim HD, Song YS, Kang SB, Lee HP. Detection of deep myometrial invasion in endometrial carcinoma: comparison of transvaginal ultrasound, CT, and MRI. J Comput Assist Tomogr 1995;19:766–72. (Level II-3) [PubMed]
153. Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798–803. (Level III) [PubMed] [Full Text]
154. Lee TS, Kim JW, Kim TJ, Cho CH, Ryu SY, Ryu HS, et al. Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group. Gynecol Oncol 2009;115:26–31. (Level II-3) [PubMed] [Full Text]
155. Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009;27:1214–9. (Level II-3) [PubMed] [Full Text]
156. Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 2005;106: 693–9. (Level III) [PubMed] [Obstetrics & Gynecology]
157. Chao AS, Chao A, Wang CJ, Lai CH, Wang HS. Obstetric outcomes of pregnancy after conservative treatment of endometrial cancer: case series and literature review. Taiwan J Obstet Gynecol 2011;50:62–6. (Level III) [PubMed]
158. Gemer O, Arie AB, Levy T, Gdalevich M, Lorian M, Barak F, et al. Lymphvascular space involvement compromises the survival of patients with stage I endometrial cancer: results of a multicenter study. Eur J Surg Oncol 2007;33:644–7. (Level II-3) [PubMed]
159. Taskiran C, Yuce K, Geyik PO, Kucukali T, Ayhan A. Predictability of retroperitoneal lymph node metastasis by using clinicopathologic variables in surgically staged endometrial cancer. Int J Gynecol Cancer 2006;16: 1342–7. (Level II-3)[PubMed]
160. Salani R, Backes FJ, Fung MF, Holschneider CH, Parker LP, Bristow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:466–78. (Level III) [PubMed] [Full Text]
161. Greer BE, Koh WJ, Abu-Rustum N, Bookman MA, Bristow RE, Campos SM, et al. Uterine Neoplasms. Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2009;7:498–531. (Level III) [PubMed] [Full Text]
162. von Gruenigen VE, Tian C, Frasure H, Waggoner S, Keys H, Barakat RR. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma: a Gynecologic Oncology Group study. Cancer 2006;107:2786–91. (Level II-2) [PubMed] [Full Text]
163. von Gruenigen V, Frasure H, Kavanagh MB, Janata J, Waggoner S, Rose P, et al. Survivors of uterine cancer empowered by exercise and healthy diet (SUCCEED): a randomized controlled trial. Gynecol Oncol 2012; 125:699–704. (Level I) [PubMed] [Full Text]
164. von Gruenigen VE, Waggoner SE, Frasure HE, Kavanagh MB, Janata JW, Rose PG, et al. Lifestyle challenges in endometrial cancer survivorship. Obstet Gynecol 2011;117:93–100. (Level II-2) [PubMed] [Full Text]
165. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:587–92. (Level I) [PubMed] [Full Text]